What results are realistic on Wegovy
In the 68-week STEP 1 trial, adults without diabetes lost an average of 14.9% of their body weight on the 2.4 mg dose — roughly 35 lb for the typical participant — versus about 2.4% on placebo. About 1 in 3 lost 20% or more (⚠ verify). That’s the number behind almost every Wegovy before-and-after you’ll see.
Read that figure carefully, because it’s easy to misread. It’s a supervised study average, measured over 68 weeks in participants who also had structured diet and activity guidance and regular clinician contact through every dose step. It is not a promise of what you personally will lose. Some people in the trial lost far more, some far less, and some stopped early because of side effects.
Wegovy weight-loss timeline
Results build slowly, and the shape of the curve matters more than any single week’s number. The first four months are dose-ramp months at strengths below the 2.4 mg trial maintenance dose — the titration schedule steps up every four weeks specifically to outrun the GI side effects, not to maximize early loss.
Early scale movement is also partly appetite change and water, not all fat. The table below maps the arc against the dose steps. Only the endpoint figures come from STEP 1; the interim pound ranges are illustrative, keyed to one example starting weight of ~220 lb, and are flagged accordingly.
| Phase | Dose step | What’s typically happening | Illustrative loss (from ~220 lb) |
|---|---|---|---|
| Weeks 1–4 | 0.25 mg | Appetite starts to quiet; some early water/scale movement | ~2–5 lb (⚠ verify, illustrative) |
| Weeks 5–8 | 0.5 mg | Smaller portions feel normal; loss becomes steadier | ~5–10 lb (⚠ verify, illustrative) |
| Weeks 9–16 | 1 mg → 1.7 mg | Ramp continues; fat loss more of the total | ~10–18 lb (⚠ verify, illustrative) |
| Week 17+ | 2.4 mg (maintenance) | Full dose; the average keeps building for months | building toward the endpoint |
| Week 68 | 2.4 mg | Trial endpoint — where the average landed | ~14.9% / ~35 lb (STEP 1) |
Two honest caveats. Most people saw roughly 6% loss by week 12 in the trial (⚠ verify) — real, but only a fraction of the eventual average, because the biggest doses come later. And the curve flattens toward week 68 rather than climbing forever; a plateau is a normal part of the arc, not a sign of failure.
What Wegovy before-and-after photos actually show (and don’t)
A dramatic side-by-side is persuasive and nearly useless as evidence. Here’s why.
- Selection bias. You only ever see the photos that went well. The people who lost less, or stopped early, don’t post. A gallery is a filter, not a sample.
- No timeframe you can trust. A photo carries no dose log, no start date, no diet or activity record. “Before and after” could be 68 weeks or two years, with or without other changes you can’t see.
- A photo can’t separate muscle from fat. Rapid loss on this drug class takes lean mass with it unless resistance training and protein intake are deliberate — so two people down the same number of pounds can look very different. What the scale says and what a photo shows can diverge for exactly this reason. Our guide on muscle loss on GLP-1s covers the protective side of that.
Published trial data has the opposite properties: a defined population, a placebo arm, a fixed protocol, and figures anyone can check against the source. That’s why this page leads with numbers.
Why individual results vary
The 14.9% average hides a wide range, and a handful of factors explain most of the spread:
- The dose you reach. Most of the trial effect sits at the 2.4 mg maintenance dose. People who stall earlier in the ramp, or drop back to 1.7 mg for tolerability, generally see less.
- Starting weight and BMI. A percentage of a larger body is more pounds; higher starting BMI often tracks with larger absolute loss.
- Diet and protein. The trial paired the drug with a reduced-calorie diet. Protein intake in particular protects muscle and shapes how the loss looks.
- Activity — especially resistance training. Movement supports the deficit and, with protein, defends lean mass during rapid loss.
- Consistency. Missed or delayed doses interrupt the appetite effect. Steady weekly dosing is part of the result.
- Plateaus. Loss naturally slows as your body adjusts. A stall after months of progress is expected, not a failure of the drug.
Keeping the weight off
The hardest part of the before-and-after isn’t the “after” — it’s holding it. In the STEP 1 extension study, people who stopped Wegovy regained about two-thirds of their lost weight within a year (⚠ verify). That isn’t a failure of willpower; obesity is a chronic condition, and removing the treatment removes the appetite effect that made the deficit sustainable.
The practical implication is that Wegovy works best framed as a long-term treatment rather than a course you finish. For most people, maintaining results means staying on a maintenance dose or building serious diet and strength-training habits before stopping — a decision to make with your prescriber, not on your own. Honest context on the ceiling of results: in the SURMOUNT-5 head-to-head trial, tirzepatide averaged 20.2% loss versus 13.7% for semaglutide over 72 weeks (⚠ verify), so if maximum average loss is your only criterion, Zepbound posted the bigger number.
Estimate your own results
The most useful thing you can do with the trial average is turn it into a range for your own starting weight — a percentage, not a photo.
Before you weigh results against side effects and cost, read the full picture: Wegovy side effects, the dosage and titration schedule, and the complete Wegovy guide. And whatever you’re considering, keep the GLP-1 safety basics in view — this is a medical decision.
Wegovy: the complete guide How semaglutide works, trial results, side effects, dosing, cost, and the new pillThis page is informational and is not medical advice. Trial figures describe supervised study participants, not expected individual results, and illustrative timeline figures are modeled ranges, not measured outcomes. Talk to a licensed clinician about your own situation. See our medical disclaimer.